H.R. 3348 · 115th Congress
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
PetersSponsor5 cosponsors · 2 D, 3 R
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
What it does: CRS summary · Introduced in House · Jul 20, 2017
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
This bill amends the Federal Food, Drug, and Cosmetic Act to include Middle East respiratory syndrome under the priority review voucher program for tropical diseases, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Latest action (Jul 20, 2017): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Jul 20, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.